Fig. 7
Inhibition of PKC-ζ by naringenin overcomes TGF-β1EV mediated radiotherapy resistance. A Schematic diagram of tumor therapy model. Tumor-bearing mice were treated by 10 Gy radiation. Naringenin (Nar, 100 mg/kg, ig) was administrated daily for 30 days. B, C Tumors were dissected and analyzed by flow cytometry for CD4+CD25+Foxp3+ (B) and ratio of CD8+/Treg (C). D The tumor weight on the 35th day after tumor inoculation were measured. E, F Survival curve and median survival days in groups of mice after different treatment combination. G Tumor growth rate in groups of mice after different treatment combination. H Rates of body weight changes. Weights of mice calculated as changes from a baseline measurement value before radiotherapy. I Number of mice which weight was lower than 15 g after different treatment combination. J The days for mice to recover to their body weight before radiation treatment in different groups. *p < 0.05. All experiments was analyzed by 2-way ANOVA